(Sharecast News) - Drugmaker AstraZeneca reported positive top-line data from its pivotal Phase III MIRANDA trial on Monday, with first‑in‑class candidate tozorakimab delivering a "statistically significant and clinically meaningful reduction" in the annualised rate of moderate‑to‑severe COPD exacerbations.
AstraZeneca said the benefit was seen in the primary population of former smokers,...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE